Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim was to study the metabolic and cardiovascular risk profile and ASP levels and to investigate the effects of GH treatment.

Why It Was Studied

Reports on the cardiovascular and metabolic risk profile in children with Prader-Willi syndrome (PWS) and the effects of GH treatment are scarce.

Acylation-stimulating protein (ASP) stimulates glucose uptake and triglyceride storage in adipose tissue.

Who Took Part

PubMed indexes the participants as infants, young children and children, both men and women.

Eighty-five children with PWS (mean +/- sd age of 4.9 +/- 3.0 yr) participated in the study.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The researchers conducted a randomized controlled GH trial.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Aging, Anthropometry, Blood Pressure, Body Height, Cardiovascular Diseases and Chromosome Deletion.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.